KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Pacira BioSciences (PCRX) over the last 17 years, with Q3 2025 value amounting to $45.3 million.

  • Pacira BioSciences' Shares Outstanding (Weighted Average) fell 218.72% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year decrease of 218.72%. This contributed to the annual value of $46.2 million for FY2024, which is 4.98% up from last year.
  • Latest data reveals that Pacira BioSciences reported Shares Outstanding (Weighted Average) of $45.3 million as of Q3 2025, which was down 218.72% from $45.9 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Shares Outstanding (Weighted Average) registered a high of $46.5 million during Q1 2024, and its lowest value of $43.8 million during Q1 2021.
  • Over the past 5 years, Pacira BioSciences' median Shares Outstanding (Weighted Average) value was $45.9 million (recorded in 2025), while the average stood at $45.6 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 455.7% in 2021, then tumbled by 218.72% in 2025.
  • Pacira BioSciences' Shares Outstanding (Weighted Average) (Quarter) stood at $44.3 million in 2021, then grew by 2.84% to $45.5 million in 2022, then rose by 1.54% to $46.2 million in 2023, then grew by 0.05% to $46.2 million in 2024, then fell by 2.14% to $45.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $45.3 million in Q3 2025, compared to $45.9 million in Q2 2025 and $46.3 million in Q1 2025.